| Objective:Nowadays,hepatitis cirrhosis is the main cause of primary liver cancer in China.Although antiviral therapy can stop the progression of liver cirrhosis and reduce the incidence and recurrence of liver cancer,it cannot completely block the occurrence of hepatocellular carcinoma.Therefore,it is of great significance to study the risk factors of liver cancer in patients with liver cirrhosis,to reduce the incidence of liver cancer,to advance the quality of life and extend the survival time of this part of patients.Methods:To collect antiviral treatment for at least 12 months of liver cirrhosis,according to whether the progression of HCC into HCC Group and NHCC(non-hepatocellular carcinoma)Group.To collect and compare the clinical data of the two groups,including sex,age,hepatitis B and liver cancer family history,whether drinking history(more than 5 years),whether there is a history of diabetes,12 weeks and 24 weeks of viral responses(HBV DNA below the minimum detection value),antiviral drugs for drug resistance,and the situation for HBe Ag seroconversion,HBV DNA,AFP,Plasma prothrombin time,ALT,AST,GGT,ALB,TBIL,PLT,Child-Pugh Level before antiviral therapy.In order to determine the risk factors of hepatocellular carcinoma,the multivariate cox regression analysis was performed on the independent variables in the two groups with statistically substantial difference.Results:A total of 72 patients were collected according to the inclusion criteria,including21 cases of HCC group,and 51 cases of NHCC group.The P value of gender(20 male patients in HCC group;37 male patients in NHCC Group),family history of Hepatitis B and HCC(5 cases of HBV family history in liver cancer Group,1 cases of liver cancer family history,12 cases of HBV family history and liver cancer family history in 5 cases),24 weeks viral response(8 cases in HCC group,33 cases in NHCC group)are less than0.05,they are statistically substantial.The P value of the age(Average of HCC group is54.8±2.4;Average of NHCC Group is 50.0±1.4),drinking history >5(2 cases of HCC Group,3 cases of non-hepatocellular carcinoma),diabetes mellitus(HCC Group 5 cases,non-hepatocellular carcinoma Group 8 cases),the ALB(Average of HCC group is 35.7±1.9;Average of NHCC Group is 37.3±1.1),the TBIL(Average of HCC group is 31.5± 3.8;Average of NHCC Group is 43.6±12.2),the PLT(Average of HCC group is 75.9±8.3;Average of NHCC Group is 100.6±7.0),the ALT(Average of HCC group is 44.1±5.1;Average of NHCC Group is 89.2±18.1),the AST(Average of HCC group is 52.0±4.2;Average of NHCC Group is 101.2±26.3),the GGT(Average of HCC group is 80.5±13.1;Average of NHCC Group is 75.6±10.4),the AFP(Average of HCC group is 75.5±57.1;Average of NHCC Group is 33.1±12.4),the plasma prothrombin time(16.4±0.5in HCC group,16.2 ± 0.5 in non-hepatocarcinoma group),the situation for HBe Ag seroconversion(10 cases of HBe Ag positive in HCC group,20 cases of HBe Ag positive in NHCC group),HBV DNA(the average of HCC group is 3.3 ±1.6E6;the average of NHCC Group is 7.0±2.0E6),whether antiviral drugs are resistant to drugs(4 cases of drug resistance in HCC group,10 cases of drug resistance in NHCC group),12 weeks viral response(8 cases in HCC group,21 cases in NHCC group),Child-pugh Grading(HCC Group A Level 9 cases,B Class 8 cases,Class C 4 cases;NHCC Group A level 31 cases,B class 10 cases,C class 10 cases)are less than 0.05,they are no statistically substantialt.Using multivariate cox regression to analyze the 3 meaningful results shows that the P value of gender,viral responses(Antiviral treatment for 3or 6 months HBV is negative)are less than 0.05.Conclusion:In patients with liver cirrhosis receiving antiviral treatment,male patients and viral responses(HBV is negative after antiviral treatment for 6 months)are independent risks factor for primary hepatocellular carcinoma.For this part of the population should be focused monitoring and follow-up. |
PDF Full Text Request